Johnson & Johnson has agreed to pay $5.5 billion to settle lawsuits alleging that its talc-based products caused ovarian cancer, covering nearly 80,000 outstanding claims. The proposed settlement requires support from 95% of eligible claimants to become effective, and previous settlement plans have fallen through. A federal judge recently questioned key expert testimonies linking talc to individual cancer cases and disqualified one plaintiffs' law firm, tilting things in the company's favor. If finalized, the settlement could reduce legal uncertainty that has weighed on Johnson's shares and management attention for years. Hedge fund interest in Johnson & Johnson rose to 113 funds at the end of Q1 2026, up from 104 in the previous quarter, with Fisher Asset Management boosting its position by 5% to $2.26 billion.
Johnson & JohnsonAgreement to pay $5.5 billion to settle talc lawsuits reduces legal uncertainty for Johnson & Johnson.
AbbVie Inc